Abstract Background and Objectives Giving the human papillomavirus (HPV) vaccination to
females has been shown to be cost-effective in most countries. The epidemiological …

Background As with many high-income countries, vaccination coverage against human
papilloma virus (HPV) infection is not high in New Zealand (NZ) at 47% in school-aged girls …

Introduction: The kinds of costs included in cost-effectiveness analyses (CEAs) for vaccines,
such as direct medical costs and indirect costs, may affect their outcomes. While some …

(1) Background: Hungarys's estimated cervical cancer mortality was 6.9/100,000 in 2012,
above the average of the EU27 countries (3.7/100,000) in the same year. Since 2014, the …

Background Although cervical cancer is a preventable disease, the clinical and economic
burdens of cervical cancer are still substantial issues in Indonesia. Objectives The main …

In Germany, vaccination against the most oncogenic HPV types 16/18 is recommended by
the Standing Committee on Vaccination (STIKO) for 12–17 year old girls since March 2007 …

Introduction: Many economic evaluations of HPV vaccination have been published, but most
have focused on the prevention of cervical disease as a primary health outcome. The cost …

Introduction: Vaccine herd effects are the indirect protection that vaccinated persons provide
to those who remain susceptible to infection, due to the reduced transmission of infections …

In Canada, the human papillomavirus (HPV) vaccine is licensed and recommended for
females and males. Although all Canadian jurisdictions fund school-based HPV vaccine …

Objectives China suffers from high burdens of human papillomavirus (HPV) and cervical
cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV …